Selank

Research suggests Selank, as a tuftsin analog, is associated with tuftsin-related receptor sites linked to immune and microglial cells rather than a single classical neurotransmitter receptor. In study models it is described as modulating GABAergic and serotonergic tone indirectly rather than binding those receptors as a primary agonist. Its anxiolytic-like profile in research is often attributed to shifting the balance of inhibitory and excitatory signaling without the sedation associated with direct GABA-A binding.

In study models, Selank is associated with influence over enkephalin-degrading enzyme activity, which research links to slower breakdown of endogenous regulatory peptides. Downstream, it has been studied in connection with expression of genes tied to neurotrophic and inflammatory signaling, including BDNF-associated pathways in preclinical work. These intracellular effects are described as supporting cellular signaling balance rather than driving a single dominant cascade.

Selank is studied for relevance to CNS signaling, with research exploring associations to GABAergic, serotonergic, and dopaminergic modulation that may relate to calm, alert states. In study models it has been examined for connections to monoamine balance and stress-related neurochemistry without the cognitive dulling seen with conventional sedatives. Findings remain preliminary and are framed around neuromodulation rather than a defined therapeutic neural mechanism.

Because Selank derives from tuftsin, research explores its immunomodulatory profile, including associations with cytokine balance and innate immune cell activity. In study models it is also examined for relevance to the stress axis and autonomic tone, where it is described as supporting a more regulated response to physiological stressors. These systemic effects are characterized as balancing rather than broadly stimulating or suppressive.